Appendix Table 8.
Relative Hazard (95% Confidence Interval)
|
||||
---|---|---|---|---|
Estimating Equation Category (mL/min/1.73m2) |
Age Adjusted Incidence Rate per 1,000 PersonYears (95% CI) |
Unadjusted | Base Model* | Final Model** |
CKD-EPIcr, cysc | ||||
Q4: ≥83 | 6.45 (3.85, 9.05) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
Q3:71 to <83 | 9.32 (6.61, 12.03) | 1.76 (1.11, 2.77) | 1.34 (0.84, 2.12) | 1.31 (0.82, 2.09) |
Q2:58 to <71 | 11.60 (8.08, 15.12) | 2.23 (1.44, 3.46) | 1.43 (0.91, 2.25) | 1.33 (0.84, 2.11) |
Q1:<58 | 18.24 (14.28, 22.19) | 4.95 (3.31, 7.41) | 2.44 (1.58, 3.77) | 1.92 (1.23, 2.99) |
p-trend | – | <0.001 | <0.001 | 0.002 |
BIS2 | ||||
Q4: ≥71 | 8.96 (4.09, 13.84) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
Q3:63 to <71 | 10.24 (7.30, 13.18) | 1.82 (1.16, 2.86) | 1.43 (0.90, 2.27) | 1.42 (0.89, 2.27) |
Q2:53 to <63 | 10.94 (7.42, 14.47) | 2.03 (1.30, 3.17) | 1.31 (0.82, 2.08) | 1.23 (0.77, 1.97) |
Q1:<53 | 18.08 (14.10, 22.07) | 5.18 (3.47, 7.74) | 2.43 (1.55, 3.81) | 1.89 (1.20, 2.98) |
p-trend | – | <0.001 | <0.001 | 0.008 |
CKD-EPIcr | ||||
Q4: ≥82 | 9.75 (5.77, 13.72) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
Q3: 73 to <82 | 9.50 (6.85, 12.15) | 1.29 (0.86, 1.94) | 0.88 (0.58, 1.34) | 0.83 (0.54, 1.28) |
Q2:61 to <73 | 10.96 (8.12, 13.80) | 1.56 (1.05, 2.32) | 0.99 (0.65, 1.49) | 0.94 (0.62, 1.43) |
Q1:<61 | 15.09 (11.93, 18.25) | 2.88 (2.01, 4.14) | 1.43 (0.96, 2.12) | 1.13 (0.75, 1.70) |
p-trend | – | <0.001 | 0.014 | 0.22 |
CKD-EPIcysc | ||||
Q4:≥82 | 8.75 (4.57, 12.94) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
Q3:67 to <82 | 9.42 (6.54, 12.31) | 1.56 (1.00, 2.45) | 1.23 (0.78, 1.94) | 1.21 (0.77, 1.92) |
Q2:53 to <67 | 10.93 (7.49, 14.37) | 1.96 (1.27, 3.03) | 1.20 (0.76, 1.88) | 1.12 (0.71, 1.77) |
Q1:<53 | 19.69 (15.50, 23.89) | 4.90 (3.31, 7.25) | 2.39 (1.56, 3.66) | 1.84 (1.19, 2.85) |
p-trend | – | <0.001 | <0.001 | 0.003 |
Abbreviations: eGFR, estimated glomerular filtration rate; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; cr, creatinine; cysc, cystatin c; BIS, Berlin Initiative Study
adjusted for age, race, and body mass index
adjusted for age, race, body mass index, hypertension, diabetes mellitus, congestive heart failure, coronary heart disease, and stroke